Russell Investments Group Ltd. lifted its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 41.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 170,089 shares of the biotechnology company’s stock after acquiring an additional 49,785 shares during the period. Russell Investments Group Ltd. owned 0.85% of Ligand Pharmaceuticals worth $53,131,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of LGND. Maryland State Retirement & Pension System raised its stake in Ligand Pharmaceuticals by 51.7% during the third quarter. Maryland State Retirement & Pension System now owns 4,433 shares of the biotechnology company’s stock worth $1,385,000 after purchasing an additional 1,510 shares during the period. Jacobi Capital Management LLC acquired a new position in shares of Ligand Pharmaceuticals in the 3rd quarter valued at $31,000. Jefferies Financial Group Inc. acquired a new position in shares of Ligand Pharmaceuticals in the 3rd quarter valued at $1,335,000. Illinois Municipal Retirement Fund grew its stake in shares of Ligand Pharmaceuticals by 4.7% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 10,144 shares of the biotechnology company’s stock valued at $3,169,000 after buying an additional 453 shares during the period. Finally, Lido Advisors LLC grew its stake in shares of Ligand Pharmaceuticals by 11.6% during the 3rd quarter. Lido Advisors LLC now owns 2,809 shares of the biotechnology company’s stock valued at $877,000 after buying an additional 292 shares during the period. 91.28% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms have recently commented on LGND. Leerink Partners began coverage on Ligand Pharmaceuticals in a report on Friday, August 14th. They set an “outperform” rating and a $330.00 price objective for the company. Barclays increased their target price on Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 11th. HC Wainwright reiterated a “buy” rating and issued a $358.00 target price on shares of Ligand Pharmaceuticals in a report on Thursday, September 24th. Weiss Ratings downgraded Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a research report on Monday, November 2nd. Finally, Citigroup upped their price target on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $355.38.
View Our Latest Analysis on LGND
Ligand Pharmaceuticals Price Performance
Ligand Pharmaceuticals stock opened at $308.79 on Monday. The firm has a fifty day moving average of $301.71 and a 200-day moving average of $258.02. Ligand Pharmaceuticals Incorporated has a 52-week low of $175.89 and a 52-week high of $326.63. The company has a quick ratio of 1.19, a current ratio of 1.22 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $6.18 billion, a P/E ratio of 137.85, a PEG ratio of 5.39 and a beta of 1.16.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last posted its earnings results on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.34. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The business had revenue of $78.75 million for the quarter, compared to analyst estimates of $77.00 million. During the same quarter in the previous year, the business posted $3.09 EPS. The business’s quarterly revenue was down 31.8% on a year-over-year basis. As a group, analysts predict that Ligand Pharmaceuticals Incorporated will post 2.35 EPS for the current year.
Insider Activity at Ligand Pharmaceuticals
In other Ligand Pharmaceuticals news, insider Andrew Reardon sold 5,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $313.22, for a total transaction of $1,566,100.00. Following the transaction, the insider owned 31,854 shares in the company, valued at $9,977,309.88. The trade was a 13.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jason Aryeh sold 3,000 shares of the business’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $320.05, for a total value of $960,150.00. Following the transaction, the director owned 105,476 shares in the company, valued at approximately $33,757,593.80. This represents a 2.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 21,593 shares of company stock worth $6,585,447. Corporate insiders own 5.60% of the company’s stock.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Featured Articles
- Five stocks we like better than Ligand Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
